The Comparative Cardiovascular and Renal Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Scandinavian Cohort Study
Diabetes Obes Metab 2022;24:473–85 doi: 10.1111/dom.14598
Ueda et al. aimed to assess the comparative cardiovascular and renal effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in routine clinical practice. A cohort study of nationwide registers from Sweden, Denmark and Norway was conducted using data from 2013–2018. Co‑primary outcomes analysed using intention-to-treat exposure definition, were MACE (myocardial infarction, stroke, and cardiovascular death), heart failure and serious renal events.